Analysed ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) News Sources
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
21-04-2026
yahoo.com
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
17-04-2026
yahoo.com
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone
13-04-2026
yahoo.com
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
09-04-2026
yahoo.com
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01-04-2026
yahoo.com
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
26-03-2026
yahoo.com
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
17-03-2026
yahoo.com
What is the current price of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)?
The current price of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) is $3.99.
ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) absolute price change since previous trading day?
The absolute price change of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) since the previous trading day is $-0.04.
ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) percentage price change since previous trading day?
The percentage price change of ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) since the previous trading day is -0.9926%.
What is the most recent average sentiment score for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)?
The most recent average sentiment score for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)?
The most recent sentiment for ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ) is .
SEC-8K** Filing Available For ZENTALIS PHARMACEUTICALS INC (ZNTL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.